AMCP CEO Susan A. Cantrell spoke with Managed Healthcare Executive® about Preapproval Information Exchange (PIE) Act of 2022, which would allow drug manufacturers to share information about a drug with payers before the drug is approved. Cantrell says passage of the PIE Act would speed up patient access to new medications.
Payers are bracing themselves for more ultra-expensive gene therapies.
Israeli researchers find more than a fivefold risk of developing systemic sclerosis among people with vitiligo.
The $8.9 billion deal comes on the heels of multibillion dollar healthcare acquisitions this year by Amazon and CVS Health. Will the spree continue?
Overall survival is considered a more definitive end point. But according to Vinay Prasad, M.D., M.P.H., and colleagues , drugs approved based on progression-free survival and overall response rate were priced higher than those approved based on overall survival.
Findings by researchers at Epic, the electronic health record company, show that the benefits extend to people ages 50-64.
If South Dakota voters approve a ballot initiative on Nov. 8, that will leave 11 states that have not expanded their Medicaid programs under the ACA.
The program reduced per-episode spending as intended, the researchers found. But those savings were offset by bonuses paid to hospitals for beating financial benchmarks, leading to a net loss.
The FDA approved Tecvayli (teclistamab) yesterday after approving two CAR-T therapies as late-line treatments for multiple myeloma earlier this year. Because it is ‘off the shelf,’ Tecvayli may have advantages over the CAR-T therapies, which are custom made for each patient and involve harvesting the patient's T cells.
Findings by researchers at Epic, the electronic health record company, show that the benefits extend to people ages 50-64.
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends. Chaet also addressed the status of select payment models like bundled and episodic, and more.
Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing and CMS value-based trends vs commercial payer trends.
Attendance rebounded to pre-pandemic levels at the AMCP Nexus 2022 meeting in National Harbor, Maryland, and very few attendees worse masks.
A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
EQRx has said it will price its PD-1/PDL-1 inhibitor 40% below the price of the entrenched PD-1/PDL-1 inhibitors, says Bhavesh Shah of Boston Medical Center Health System. But there are obstacles looming, including the development of combination therapies.
A real-world study by the PBM shows major benefits from the new cystic fibrosis drug when it comes to hospitalizations and pulmonary exacerbations. But total cost of care of patients tripled because the drug is expensive.
Express Scripts' Aimee Tharaldson discussed the growing number of gene therapies in her keynote talk today on specialty drug at AMCP Nexus 2022. She listed 12 approved gene therapies, eight in the near-term pipeline for hemophilia and another seven for other diseases that may be approved next year.
Research by Janssen shows that non-White patients are disproportionately affected by the accumulators and maximizers that PBMs use to blunt the financial consequences of copay assistance cards.
There is a crescendo of policies and programs for healthcare interoperability and electronic prior authorization, but it is a complicated proposition, says Kim Boyd at AMCP Nexus 2022.
Yuqian Liu, Pharm.D., and Michelle Booth, Pharm.D., of Magellan Rx Management, discuss the background and consequences of step therapy in Medicare Part B in an interview prior to their session at the AMCP Nexus 2022 meeting in National Harbor, Maryland.
The former Baltimore city health commissioner has been criticized for some of her views on COVID-19 mandates. In her talk opening the AMCP Nexus 2022 meeting, Wen said that if public health officials don’t take into account public attitudes, it could affect the ability to deal with future public health emergencies.
The former Baltimore city health commissioner’s positions on COVID-19 and other issues drawn some strong criticism. Former FDA Commissioner Scott Gottlieb is among those that have come to her defense.
Samsung Bioepis executive Tom Newcomer’s touts the 10-year-old biosimilar company’s achievements as it gets ready to launch its Humira biosimilar, Hadlima.
Hadlima is scheduled to be on to the market in July 2023. In an interview with Managed Healthcare Executive®, a Samsung Bioepis executive says data on Hadlima’s interchangeability won’t be ready till 2024.
Tom Newcomer, head of U.S. market access for the maker of Humira biosimilar Hadlima, deflected questions on price but touted the drug’s track record overseas.
Tom Newcomer, head of U.S. market access for Samsung Bioepis, maker of Hadlima, a Humira biosimilar, said some potential customers want to see which biosimilars will grab a large market share before deciding on which one to buy
Watts, chief emergency management medical officer, director of global health and a pediatric emergency medicine physician at Children’s Mercy Kansas City, is one of 10 winners in this year's Emerging Industry Leaders series.
Russell, senior vice president of government markets at Priority Health, a health plan in Grand Rapids, Michigan, is one of 10 winners in this year's Emerging Industry Leaders series.
Mechanic, director of telehealth and medical director at Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center in Boston, is one of 10 winners in this year's Emerging Industry Leaders series.
